New daily shot could ease rare hormone disorder
NCT ID NCT04009291
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a daily injection called TransCon PTH in 59 adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. Participants were randomly assigned to receive either the drug or a placebo for four weeks, followed by an open-label extension where everyone received the drug. The goal was to see if the injection could safely bring calcium levels back to normal and reduce the need for supplements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TransCon PTH (a daily injection of parathyroid hormone)
What this could lead to
If successful, this could provide a more effective way to manage hypoparathyroidism, potentially reducing the need for high doses of calcium and vitamin D supplements.
What could go wrong
This is an early-phase trial with only 59 participants, so results may not apply to everyone. The treatment requires daily injections and may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
Chicago, Illinois, 60637, United States
-
Ascendis Pharma Investigational Site
Rochester, Minnesota, 55901, United States
-
Ascendis Pharma Investigational Site
Great Neck, New York, 11021, United States
-
Ascendis Pharma Investigational Site
New York, New York, 10032, United States
-
Ascendis Pharma Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
Ascendis Pharma Investigational Site
Oakville, Ontario, L6M 1M1, Canada
-
Ascendis Pharma Investigational Site
Aalborg, 9000, Denmark
-
Ascendis Pharma Investigational Site
Aarhus, 8200, Denmark
-
Ascendis Pharma Investigational Site
Copenhagen, 2200, Denmark
-
Ascendis Pharma Investigational Site
Dresden, 01307, Germany
-
Ascendis Pharma Investigational Site
Bologna, 40138, Italy
-
Ascendis Pharma Investigational Site
Milan, 20132, Italy
-
Ascendis Pharma Investigational Site
Pisa, 56124, Italy
-
Ascendis Pharma Investigational Site
Rome, 00128, Italy
-
Ascendis Pharma Investigational Site
Oslo, 0176, Norway